PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P cut its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 2.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,207,060 shares of the company’s stock after selling 36,207 shares during the period. Loomis Sayles & Co. L P owned approximately 2.31% of PROCEPT BioRobotics worth $97,192,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Raleigh Capital Management Inc. purchased a new position in PROCEPT BioRobotics during the fourth quarter worth approximately $32,000. Signaturefd LLC lifted its holdings in PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after acquiring an additional 145 shares during the last quarter. IFP Advisors Inc purchased a new position in PROCEPT BioRobotics in the fourth quarter worth approximately $58,000. Wilmington Savings Fund Society FSB purchased a new stake in PROCEPT BioRobotics in the 3rd quarter valued at about $64,000. Finally, Arcadia Investment Management Corp MI purchased a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at approximately $64,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PRCT has been the subject of a number of recent research reports. Morgan Stanley decreased their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Truist Financial reissued a “buy” rating and issued a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Finally, Wells Fargo & Company restated an “overweight” rating and issued a $112.00 price objective on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, PROCEPT BioRobotics currently has an average rating of “Moderate Buy” and a consensus price target of $94.29.

PROCEPT BioRobotics Stock Down 0.3 %

Shares of NASDAQ:PRCT opened at $62.33 on Thursday. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -31.96 and a beta of 1.05. The stock’s 50-day moving average price is $66.32 and its two-hundred day moving average price is $78.15. PROCEPT BioRobotics Co. has a 12-month low of $45.56 and a 12-month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. On average, research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares of the company’s stock, valued at $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Kevin Waters sold 733 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares of the company’s stock, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,455 shares of company stock worth $368,322 over the last quarter. 17.40% of the stock is owned by corporate insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).